Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

HCW Biologics Inc. - Common Stock (NQ:HCWB)

6.074 +0.124 (+2.08%)
Streaming Delayed Price Updated: 11:26 AM EDT, Jun 6, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about HCW Biologics Inc. - Common Stock

Spotlight on Undervalued Nasdaq Stocks: HCWB, CRDL, NIVF, SINT, APLM – A Must-Watch This Week!
Via AB Newswire
Investigator Sponsor of HCW Biologics’ Phase 1 Clinical Trial Presented Human Data Readout and Anti-Cancer Mechanism of Action of HCW9218 at 38th SITC Annual Meeting
From HCW Biologics, Inc
Via GlobeNewswire
Masonic Cancer Center, University of Minnesota to Present Data in Poster Presentation Human Data Readout for Phase 1 Study to Evaluate HCW9218 in Solid Tumors at SITC 38th Annual Meeting
HCW9218 is the lead product candidate of HCW Biologics Inc. 
From HCW Biologics, Inc
Via GlobeNewswire
HCW Biologics Participating at H.C. Wainwright 25th Annual Global Investment Conference in New York on September 11 – 13, 2023
Company will provide an update for clinical development and intellectual property programs, Including recent achievements and expected milestones in the next 12 months 
From HCW Biologics, Inc
Via GlobeNewswire
HCW Biologics Secures $26.25 Million Non-Dilutive Financing With Asset-Backed Development Loan
From HCW Biologics, Inc
Via GlobeNewswire
HCW Biologics Enters CRADA with National Cancer Institute
NCI Activated as Clinical Site for Phase 1b/2 Clinical Trial to Evaluate HCW9218 in Advanced Pancreatic Cancer 
From HCW Biologics, Inc
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.